Joint Formulary & PAD

Rasagiline mesilate - Parkinson's disease

You are here : Home > Formulary Search > Rasagiline mesilate - Parkinson's disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :

Documentation

Guidelines (National)
NICE NG71 Parkinsons-disease-in-adults

PAD Profile

ChemicalSubstance :
Rasagiline mesilate
Indication :
Parkinson's disease
Group Name :
Keywords :
Parkinsons disease, PD, monoamine-oxidase-B inhibitors, MAOB
Brand Names Include :
Azilect
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

06 Jun 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
  • Monoamine-oxidase-B inhibitors (rasagiline, selegiline), (or levodopa or dopamine agonists) are a first-line treatment option in the early stages of Parkinson's disease where motor symptoms do not impact quality of life.
  • Monoamine-oxidase-B inhibitors are a choice of adjuvant treatment in patients who have developed dyskinesia or motor fluctuations despite optimal levodopa therapy.

Patients in whom Parkinson's is suspected should be referred quickly and untreated to a specialist.

Initiation may be carried out in Primary Care but only after recommendation by a specialist.
Modifications to therapy should only be carried out on specialist advice.

Prescribers are reminded to prescribe generically and not by brand.

 

Other Indications

Below are listed other indications that Rasagiline mesilate is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Parkinson's disease.